PMID- 25621840
OWN - NLM
STAT- MEDLINE
DCOM- 20160101
LR  - 20230607
IS  - 1879-0372 (Electronic)
IS  - 0952-7915 (Print)
IS  - 0952-7915 (Linking)
VI  - 33
DP  - 2015 Apr
TI  - Designing chimeric antigen receptors to effectively and safely target tumors.
PG  - 9-15
LID - S0952-7915(15)00003-5 [pii]
LID - 10.1016/j.coi.2015.01.002 [doi]
AB  - The adoptive transfer of T cells engineered to express artificial chimeric 
      antigen receptors CARs) that target a tumor cell surface molecule has emerged as 
      an exciting new approach for cancer immunotherapy. Clinical trials in patients 
      with advanced B cell malignancies treated with CD19-specific CAR-modified T cells 
      (CAR-T) have shown impressive antitumor efficacy, leading to optimism that this 
      approach will be useful for treating common solid tumors. Because CAR-T cells 
      recognize tumor cells independent of their expression of human leukocyte antigen 
      (HLA) molecules, tumors that escape conventional T cells by downregulating HLA 
      and/or mutating components of the antigen processing machinery can be eliminated. 
      The ability to introduce or delete additional genes in T cells has the potential 
      to provide therapeutic cell products with novel attributes that overcome 
      impediments to immune mediated tumor elimination in immunosuppressive tumor 
      microenvironments. This review will discuss recent concepts in the development of 
      effective and safe synthetic CARs for adoptive T cell therapy (ACT).
CI  - Copyright (c) 2015 Elsevier Ltd. All rights reserved.
FAU - Jensen, Michael C
AU  - Jensen MC
AD  - Seattle Children's Research Institute, Seattle, WA, United States; University of 
      Washington, Seattle, WA, United States; Fred Hutchinson Cancer Research 
      Institute, Seattle, WA, United States. Electronic address: 
      Michael.jensen@seattlechildrens.org.
FAU - Riddell, Stanley R
AU  - Riddell SR
AD  - University of Washington, Seattle, WA, United States; Fred Hutchinson Cancer 
      Research Institute, Seattle, WA, United States; Institute for Advanced Study, 
      Technical University of Munich, Munich, Germany.
LA  - eng
GR  - CA136551/CA/NCI NIH HHS/United States
GR  - P51 OD010425/OD/NIH HHS/United States
GR  - P50CA132393/CA/NCI NIH HHS/United States
GR  - R01 AI053193/AI/NIAID NIH HHS/United States
GR  - R01 CA114536/CA/NCI NIH HHS/United States
GR  - R01 CA136551/CA/NCI NIH HHS/United States
GR  - AI053193/AI/NIAID NIH HHS/United States
GR  - CA114536/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Review
DEP - 20150123
PL  - England
TA  - Curr Opin Immunol
JT  - Current opinion in immunology
JID - 8900118
RN  - 0 (Receptors, Antigen, T-Cell)
RN  - 0 (Recombinant Fusion Proteins)
SB  - IM
MH  - Animals
MH  - Cell- and Tissue-Based Therapy
MH  - Humans
MH  - *Immunotherapy, Adoptive/adverse effects/methods
MH  - Neoplasms/genetics/*immunology/metabolism/*therapy
MH  - *Receptors, Antigen, T-Cell/genetics/metabolism
MH  - *Recombinant Fusion Proteins/genetics/metabolism
MH  - T-Lymphocytes/*immunology/metabolism
PMC - PMC4397136
MID - NIHMS658435
EDAT- 2015/01/27 06:00
MHDA- 2016/01/02 06:00
PMCR- 2016/04/01
CRDT- 2015/01/27 06:00
PHST- 2014/12/11 00:00 [received]
PHST- 2014/12/30 00:00 [revised]
PHST- 2015/01/01 00:00 [accepted]
PHST- 2015/01/27 06:00 [entrez]
PHST- 2015/01/27 06:00 [pubmed]
PHST- 2016/01/02 06:00 [medline]
PHST- 2016/04/01 00:00 [pmc-release]
AID - S0952-7915(15)00003-5 [pii]
AID - 10.1016/j.coi.2015.01.002 [doi]
PST - ppublish
SO  - Curr Opin Immunol. 2015 Apr;33:9-15. doi: 10.1016/j.coi.2015.01.002. Epub 2015 
      Jan 23.